Medigene AG (WBO:MDG2)
€ 1.1 0.026 (2.42%) Market Cap: 16.06 Mil Enterprise Value: 4.58 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 46/100

Medigene AG to Discuss Updated Corporate Strategy Call Transcript

Nov 16, 2022 / 02:00PM GMT
Release Date Price: €4.3 (+2.25%)
Operator

Greetings, and welcome to Medigene corporate call. (Operator Instructions) As a reminder, this conference is being recorded. I'd now like to turn the conference over to your host, Dr. Selwyn Ho, CEO. Thank you. Please go ahead, sir.

Selwyn Ho
Medigene AG - CEO

Today, I'm delighted to share with you an update of Medigene's vision and future plans, which our team have been working on since I joined in late July of this year. Before I start, I would like to point out that I will be making forward-looking statements and point you to our disclosure here.

Medigene is an early-stage platform biotech company focused on developing differentiated, best-in-class T-cell-receptor-engineered T cell or TCR-T therapies for multiple solid tumor indications. We have a proprietary end-to-end platform for developing differentiated TCR-T therapies that consist of both product enhancement technologies, such as our PD1-41BB switch receptor, as well as development optimization technologies, such as our allogeneic-HLA or allo-HLA TCR priming tool.

Our end-to-end

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot